Has MRD monitoring superseded other prognostic factors in adult ALL?BRÜGGEMANN, Monika; RAFF, Thorsten; KNEBA, Michael et al.Blood. 2012, Vol 120, Num 23, pp 4470-4481, issn 0006-4971, 12 p.Article

Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle : MOLECULAR PATHOGENESIS OF HEMATOLOGIC MALIGNANCIESBRÜGGEMANN, Monika; GÖKBUGET, Nicola; KNEBA, Michael et al.Seminars in oncology. 2012, Vol 39, Num 1, pp 47-57, issn 0093-7754, 11 p.Article

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialDREGER, Peter; DÖHNER, Hartmut; DÜHRSEN, Ulrich et al.Blood. 2012, Vol 119, Num 21, pp 4851-4859, issn 0006-4971, 9 p.Article

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphomaSCHMITZ, Nobert; KLOESS, Marita; GLASS, Bertram et al.Cancer. 2006, Vol 106, Num 1, pp 136-145, issn 0008-543X, 10 p.Article

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study GroupLENZ, Georg; DREYLING, Martin; KNEBA, Michael et al.Blood. 2004, Vol 104, Num 9, pp 2667-2674, issn 0006-4971, 8 p.Article

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVFABARIUS, Alice; LEITNER, Armin; JUNG-MUNKWITZ, Susanne et al.Blood. 2011, Vol 118, Num 26, pp 6760-6768, issn 0006-4971, 9 p.Article

Minimal residual disease detection in mantle cell lymphoma : methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinationsBÖTTCHER, Sebastian; RITGEN, Matthias; KNEBA, Michael et al.Haematologica (Roma). 2008, Vol 93, Num 4, pp 551-559, issn 0390-6078, 9 p.Article

C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosusMOOSIG, Frank; FÄHNDRICH, Erika; KNORR-SPAHR, Anja et al.Rheumatology international (Berlin. Print). 2006, Vol 26, Num 12, pp 1109-1112, issn 0172-8172, 4 p.Article

Risk-adapted treatment according to minimal residual disease in adult ALLGÖKBUGET, Nicola; KNEBA, Michael; RAFF, Thorsten et al.Baillière's best practice & research. Clinical haematology. 2002, Vol 15, Num 4, pp 639-652, issn 1521-6926, 14 p.Article

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study GroupFISCHER, Kirsten; CRAMER, Paula; TRESCKOW, Julia Von et al.Journal of clinical oncology. 2012, Vol 30, Num 26, pp 3209-3216, issn 0732-183X, 8 p.Article

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 TrialBÖTTCHER, Sebastian; RITGEN, Matthias; MENDILA, Myriam et al.Journal of clinical oncology. 2012, Vol 30, Num 9, pp 980-988, issn 0732-183X, 9 p.Article

Targeted Therapy With the T-Cell―Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free SurvivalTOPP, Max S; KUFER, Peter; STELLJES, Matthias et al.Journal of clinical oncology. 2011, Vol 29, Num 18, pp 2493-2498, issn 0732-183X, 6 p.Article

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission -long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)SCHWEIGHOFER, Carmen D; RITGEN, Matthias; EICHHORST, Barbara F et al.British journal of haematology. 2009, Vol 144, Num 1, pp 95-98, issn 0007-1048, 4 p.Article

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98BSCHLENK, Richard F; DÖHNER, Konstanze; HABDANK, Marianne et al.Haematologica (Roma). 2009, Vol 94, Num 1, pp 54-60, issn 0390-6078, 7 p.Article

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemiaRITGEN, Matthias; LANGE, Alexandra; STILGENBAUER, Stephan et al.Blood. 2003, Vol 101, Num 5, pp 2049-2053, issn 0006-4971, 5 p.Article

Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemiaHOELZER, Dieter; GÖKBUGET, Nicola; DIGEL, Werner et al.Blood. 2002, Vol 99, Num 12, pp 4379-4385, issn 0006-4971Article

Treatment of adult all according to protocols of the German Multicenter Study Group for Adult ALL (GMALL)GÖKBUGET, Nicola; HOELZER, Dieter; LUDWIG, Wolf-Dieter et al.Hematology/oncology clinics of North America. 2000, Vol 14, Num 6, issn 0889-8588, ix,1307-1325 [20 p.]Article

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article

Plasmablastic Posttransplant Lymphoma: Cytogenetic Aberrations and Lack of Epstein-Barr Virus Association Linked With Poor Outcome in the Prospective German Posttransplant Lymphoproliferative Disorder RegistryZIMMERMANN, Heiner; OSCHLIES, Ilske; ANAGNOSTOPOULOS, Ioannis et al.Transplantation. 2012, Vol 93, Num 5, pp 543-550, issn 0041-1337, 8 p.Article

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLTOPP, Max S; GÖKBUGET, Nicola; STELLJES, Matthias et al.Blood. 2012, Vol 120, Num 26, pp 5185-5187, issn 0006-4971, 3 p.Article

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study GroupFISCHER, Kirsten; CRAMER, Paula; KRANZ, Gabriele et al.Journal of clinical oncology. 2011, Vol 29, Num 26, pp 3559-3566, issn 0732-183X, 8 p.Article

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment : data from the GMALL 06/99 and 07/03 trialsRAFF, Thorsten; GOKBUGET, Nicola; BRÜGGEMANN, Monika et al.Blood. 2007, Vol 109, Num 3, pp 910-915, issn 0006-4971, 6 p.Article

Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma : effects on molecular response and clinical outcomeDREGER, Peter; RIEGER, Michael; SEYFARTH, Bärbel et al.Haematologica (Roma). 2007, Vol 92, Num 1, pp 42-49, issn 0390-6078, 8 p.Article

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaWEISS, Mark A; LAMANNA, Nicole; RITGEN, Matthias et al.Blood. 2006, Vol 107, Num 3, pp 852-853, issn 0006-4971, 10 p.Article

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the V_H gene mutational statusDREGER, Peter; STILGENBAUER, Stephan; BENNER, Axel et al.Blood. 2004, Vol 103, Num 7, pp 2850-2858, issn 0006-4971, 9 p.Article